Stomach staple or semaglutide: What is more likely to keep you alive?

Embargoed until: Publicly released: 2024-06-08 01:00

International

CC:0

Israeli and US researchers say that bariatric metabolic surgery (BMS) - also known as gastric bypass surgery - is linked with a lower chance of dying from obesity if you have type 2 diabetes than peptide-1 receptor agonists (GLP-1RAs) - diabetes drugs such as semaglutide. The researchers looked into data from over 6,000 people living with diabetes for 10 years or less, and say that BMS was associated with a 62% reduction in deaths, compared to the GLP-1RAs, with weight reduction being the most important factor.

Media release

From:

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: Hasharon Hospital, Israel; Ariel University, Israel

Funder: No specific funding stated for the paper - However, Drs Dicker, Lavie, and Reges reported receiving grants from the Israel Science Foundation outside the submitted work. Dr Dicker reported receiving grants, personal fees, and nonfinancial support from NovoNordisk and Eli Lilly; and personal fees and nonfinancial support from Boehringer Ingelheim outside the submitted work. Dr Greenland reported receiving grants from the National Institutes of Health and the American Heart Association outside the submitted work.

Media Contact/s

Contact details are only visible to registered journalists.